BSE Live
Apr 16, 16:01Prev. Close
41.27
Open Price
41.98
Bid Price (Qty.)
41.06 (35)
Offer Price (Qty.)
41.13 (500)
NSE Live
Apr 16, 15:57Prev. Close
41.31
Open Price
41.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
41.17 (896)
| Cash Flow of Morepen Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 37.48 | 28.61 | 26.22 | 22.55 | 20.04 | |
| Net CashFlow From Operating Activities | 10.86 | 14.58 | 61.25 | 49.24 | 50.01 | |
| Net Cash Used In Investing Activities | -12.08 | -10.34 | -24.28 | -14.67 | -27.08 | |
| Net Cash Used From Financing Activities | 4.65 | -0.35 | -37.67 | -31.29 | -27.89 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 3.43 | 3.89 | -0.69 | 3.29 | -4.97 | |
| Cash And Cash Equivalents Begin of Year | 9.36 | 5.47 | 6.16 | 2.87 | 8.60 | |
| Cash And Cash Equivalents End Of Year | 12.79 | 9.36 | 5.47 | 6.16 | 3.63 |
16.03.2026
Morepen Lab Consolidated December 2025 Net Sales at Rs 484.16 crore, up 6.93% Y-o-Y
20.02.2026
Morepen Lab Consolidated December 2025 Net Sales at Rs 484.16 crore, up 6.93% Y-o-Y
19.02.2026
Morepen Lab Standalone December 2025 Net Sales at Rs 457.57 crore, up 13.47% Y-o-Y
26.11.2025
Morepen Lab Consolidated September 2025 Net Sales at Rs 411.58 crore, down 5.97% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth